Skip to content

Irisin Hormone as a Novel Diagnostic Marker for Detection and Progression of Diabetic Nephrophathy Patients

Evaluation of Irisin as a Novel Diagnostic Marker for Early Detection and Progression of Diabetic Nephrophathy

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07435480
Enrollment
200
Registered
2026-02-27
Start date
2026-04-01
Completion date
2028-03-01
Last updated
2026-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathies

Brief summary

Study the relation between irisin level and progression of diabetic nephropathy and its early detection.

Detailed description

Diabetes is a prevalent worldwide challenge affecting 425 million individuals, with the International Diabetes Federation (IDF) projecting a rise to 630 million by 2045. Diabetic nephropathy (DN) is a critical complication that impacts one-third of diabetic patients and significantly contributes to cardiovascular morbidity and mortality, leading to substantial socioeconomic burdens (Dwivedi and Sikarwar, 2024). Diabetic nephropathy (DN) is a multifaceted condition involving various interconnected mechanisms, primarily influenced by hyperglycemia . Diabetic nephropathy (DN) is one of the most feared diabetic chronic microvascular complications and the major cause of end-stage renal disease (ESRD). Therefore, early recognition is crucial. Presently, this relies on the albumin excretion rate (AER) and glomerular filtration rate (GFR). Irisin, an exercise - induced myokine, has been linked to metabolic disorders, but its relationship with DN remains unclear. Experimental studies have demonstrated the role of irisin in protecting mice against diabetes and obesity

Interventions

DIAGNOSTIC_TESTHBa1c

Rapid method for detection of diabetes

DIAGNOSTIC_TESTglucose

accurate method for diabetes

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
30 Years to 75 Years

Inclusion criteria

Type 2 diabetic patients

Exclusion criteria

* Non-diabetic kidney diseases. * Acute illness, infection, obesity, hypertension, type 1 DM. * Malignancy, other endocrine disorders, corticosteroid drugs, pregnancy, lactation.

Design outcomes

Primary

MeasureTime frameDescription
Measure number of Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).Two yearsParticipants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).

Contacts

CONTACTGehad Ha Abdelmegid, MD
gege1_8_1992@yahoo.com00201125745717
STUDY_DIRECTORAhmed Se Mahmoud, ass prof

Sohag University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026